- Crystalys nets $130M more to push gout drug through late-stage tests<figure><div><img src="https://imgproxy.divecdn.com/THeKNpwt2ETxP7Nf-ec1mU-DtgG84p4ktQEqFznWC1c/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODUxMTEwNjQucG5n.…BioPharma Dive · 2d ago↗ source
- Summit reports two-year survival data for Western patients, though context lackingSummit Therapeutics unveiled additional follow-up data on its experimental cancer drug ivonescimab, and how its benefit compares between Asian and Western patients. But key context remains unknown.…Endpoints · 2d ago↗ source
- Celldex scraps antibody in prurigo nodularis after Phase 2 flopCelldex said on Tuesday it will stop investigating its mast cell-targeting monoclonal antibody in a type of chronic itch disease after it failed on all efficacy measures in a mid-stage trial. Top…